Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Northwest Biotherapeutics Partners with SPIMACO for Collaboration in Saudi Arabia on DCVax® Products.
Aug 06, 2026
Contract Type
partnership
BethesdaBiotechnologyHealthcareresearch
Description
Northwest Biotherapeutics has entered into a non-binding Memorandum of Understanding with the Saudi Pharmaceutical Industries and Medical Appliance Company (SPIMACO) to collaborate on bringing its DCVax®-L product to Saudi Arabia. The partnership aims to establish a framework for approval, commercialization, and technology transfer for DCVax®-L products.
Company Information
Company
Northwest Biotherapeutics
Location
4800 MONTGOMERY LANE,
Bethesda, Maryland, United States
About
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." This Phase III trial reached data lock and the Company is actively continuing to move toward announcement of top line data. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and, as resources permit, plans to pursue Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.
BethesdaBiotechnologyHealthcareresearch